Navigation Links
Topokine Acquires Exclusive Rights to Revolutionary Technology for Manufacturing Topical Fat-Reducing Medications
Date:3/12/2013

NEWTON, Mass., March 12, 2013 /PRNewswire-iReach/ -- Topokine Therapeutics, a clinical-stage biotechnology company developing therapies for dermatology and medical aesthetics, announced today that it has entered into an exclusive license agreement with the University of Bristol.  Under the terms of the agreement, the Company has acquired exclusive worldwide rights to use, for all skin applications, a novel method to manufacture a class of prostaglandins that reduces fat.  Additional terms were not disclosed. 

The revolutionary technology, which one expert has called "unbeatable in its conciseness and elegance", greatly simplifies synthesis of prostaglandins.  It is expected to improve manufacturing efficiency by 5-10 fold and substantially reduce manufacturing costs.  The technology, featured in the September 13th, 2012 issue of Nature magazine, was developed at the University of Bristol by Professor Varinder Aggarwal and colleagues.

"There is remarkable synergy between our research and Topokine's innovative products.  I look forward to helping advance Topokine's efforts by applying our synthesis technology," said Professor Aggarwal, a Fellow of the Royal Society who has joined Topokine's Advisory Board.

"Professor Aggarwal's group is at the cutting-edge of prostaglandin chemistry," said Murat Kalayoglu, MD, PhD, Topokine President & CEO.  "This exclusive license further enhances our IP position, and we are excited to collaborate with him and the University of Bristol."

About Topokine

Topokine Therapeutics is a clinical-stage biotechnology company developing therapies for dermatology and medical aesthetics. The company's lead program, XAF5 Gel, is a skin cream being developed for local reduction of excess subcutaneous fat.  XAF5 is an adipomodulatory compound that inhibits adipocytes by engaging a cell-surface receptor, resulting in down-regulation of key adipocyte transcription factors.  XAF5 reduces adipose tissue in vivo without inflammation or necrosis.

About the University of Bristol

The University of Bristol is consistently ranked among the leaders in UK higher education.  Research-intensive and with an international reputation for quality and innovation, the University has over 18,000 students from over 100 countries, together with more than 5,000 staff.  Places at Bristol are among the most highly sought after of all UK universities.  The University was founded in 1876 and was granted its Royal Charter in 1909.  It was the first university in England to admit women on the same basis as men.  It is located in the heart of the city from which it grew, but is now a significant player on the world stage as well as a major force in the economic, social and cultural life of Bristol and South West England.  Bristol is a member of the Worldwide Universities Network and of the Russell Group of leading research-intensive universities in the UK.

Media Contact: Murat Kalayoglu Topokine Therapeutics, Inc., murat.kalayoglu@topokine.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Topokine Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Topokine Therapeutics Secures Financing from Schooner Capital to Advance Clinical Development of XAF5 Gel
2. SafeCode Drug Technologies Acquires Breakthrough Painless Injection Technology
3. Shire Acquires Premacure AB
4. BD Acquires Cato Software Solutions
5. NeuroVive Acquires Highly Potent, Novel Cyclophilin Inhibitors From Biotica
6. Dynamic Healthcare Services Acquires the operating assets of APO2, a Provider of Home Medical Equipment and Respiratory Therapy Products and Services in Hazleton, PA
7. PRA Acquires ClinStar
8. Endexx Acquires Medical Marijuana Management Technology
9. DSI Renal Acquires New Smyrna Beach Artificial Kidney Center
10. Henry Schein Acquires The Maddox Practice Group
11. Perrigo Company Acquires U.K.-based Rosemont Pharmaceuticals Ltd. For Approximately £180 Million Or $283 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... , Sept. 22, 2017  As the latest Obamacare ... Bill Cassidy (R-LA) and Lindsey Graham ... that the medical device industry is in an odd ... tax, the 2.3% excise tax on medical device sales ... also want covered patients, increased visits and hospital customers ...
(Date:9/18/2017)... KALAMAZOO, Mich. , Sept. 18, 2017  PMD ... OptiMed Specialty Pharmacy of Kalamazoo, Mich. ... strategic hub service that expedites and streamlines patient and ... Spiro PD 2.0, and wellness management services.  ... medical device used to measure lung function for a ...
(Date:9/12/2017)... LAKES, N.J. , Sept. 12, 2017  Consumer reviews on ... Embrace Hearing as the number one company for hearing aids, ... ReSound™ and fifteen other brands. ... Embrace Hearing Named #1 by Consumers For Hearing Aids ... Embrace Hearing is an online store that provides ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... , ... “America On The Brink”: the Christian history of the United States ... creation of published author, William Nowers. Captain Nowers and his wife, Millie, have ... thirty years in the Navy. Following his career as a naval aviator and ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 ... characterized by frequent cessation in breathing. Oral appliances can offer significant relief to ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company ... of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every ... meet the highest standard. , These products are also: Gluten Free, Non-GMO, ...
(Date:10/12/2017)... ... ... The American College of Medical Informatics (ACMI) will present the 2017 Morris ... of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is taking ... in the field of medical informatics, this prestigious award is presented to an individual ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the ... to develop to enable prevention of a major side effect of chemotherapy in ... in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a ...
Breaking Medicine News(10 mins):